TherapeuticsMD (NASDAQ:TXMD – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.06) earnings per share (EPS) for the quarter, Zacks reports. TherapeuticsMD had a negative return on equity of 14.08% and a negative net margin of 207.77%.
TherapeuticsMD Stock Performance
TXMD stock opened at $1.52 on Wednesday. The business has a 50 day simple moving average of $1.04 and a two-hundred day simple moving average of $1.13. TherapeuticsMD has a 1-year low of $0.70 and a 1-year high of $2.44.
Analysts Set New Price Targets
Separately, StockNews.com started coverage on shares of TherapeuticsMD in a research report on Friday, May 9th. They issued a “hold” rating for the company.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.
Featured Articles
- Five stocks we like better than TherapeuticsMD
- Learn Technical Analysis Skills to Master the Stock Market
- AppLovin Surges on Earnings: What’s Next for This Tech Standout?
- Investing in Commodities: What Are They? How to Invest in Them
- U.S. Regulators Target CrowdStrike: Is It a Signal or Noise?
- What to Know About Investing in Penny Stocks
- 3 AI ETFs Tapping Into the Heart of the AI Revolution
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.
